nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—CYP1A2—Pentoxifylline—systemic scleroderma	0.12	0.512	CbGbCtD
Phenylpropanolamine—CYP1A2—Leflunomide—systemic scleroderma	0.114	0.488	CbGbCtD
Phenylpropanolamine—Renal tubular necrosis—Mycophenolic acid—systemic scleroderma	0.0265	0.0346	CcSEcCtD
Phenylpropanolamine—Renal tubular necrosis—Mycophenolate mofetil—systemic scleroderma	0.0209	0.0273	CcSEcCtD
Phenylpropanolamine—Liver injury—Captopril—systemic scleroderma	0.0143	0.0187	CcSEcCtD
Phenylpropanolamine—Liver injury—Azathioprine—systemic scleroderma	0.0125	0.0163	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Captopril—systemic scleroderma	0.012	0.0157	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Captopril—systemic scleroderma	0.012	0.0157	CcSEcCtD
Phenylpropanolamine—Liver injury—Leflunomide—systemic scleroderma	0.0118	0.0154	CcSEcCtD
Phenylpropanolamine—Liver injury—Mycophenolic acid—systemic scleroderma	0.0112	0.0147	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Azathioprine—systemic scleroderma	0.0105	0.0137	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Leflunomide—systemic scleroderma	0.00991	0.0129	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Leflunomide—systemic scleroderma	0.00991	0.0129	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Mycophenolic acid—systemic scleroderma	0.00945	0.0123	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Mycophenolic acid—systemic scleroderma	0.00945	0.0123	CcSEcCtD
Phenylpropanolamine—Drowsiness—Pentoxifylline—systemic scleroderma	0.00888	0.0116	CcSEcCtD
Phenylpropanolamine—Liver injury—Mycophenolate mofetil—systemic scleroderma	0.00887	0.0116	CcSEcCtD
Phenylpropanolamine—Ataxia—Captopril—systemic scleroderma	0.00821	0.0107	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Mycophenolate mofetil—systemic scleroderma	0.00746	0.00974	CcSEcCtD
Phenylpropanolamine—Flushing—Pentoxifylline—systemic scleroderma	0.00739	0.00965	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Pentoxifylline—systemic scleroderma	0.00712	0.00929	CcSEcCtD
Phenylpropanolamine—Tension—Pentoxifylline—systemic scleroderma	0.00681	0.00889	CcSEcCtD
Phenylpropanolamine—Nervousness—Pentoxifylline—systemic scleroderma	0.00674	0.0088	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Mycophenolic acid—systemic scleroderma	0.0067	0.00875	CcSEcCtD
Phenylpropanolamine—Vision blurred—Pentoxifylline—systemic scleroderma	0.00654	0.00853	CcSEcCtD
Phenylpropanolamine—Urinary retention—Mycophenolic acid—systemic scleroderma	0.00653	0.00852	CcSEcCtD
Phenylpropanolamine—Tremor—Pentoxifylline—systemic scleroderma	0.0065	0.00848	CcSEcCtD
Phenylpropanolamine—Ataxia—Mycophenolic acid—systemic scleroderma	0.00645	0.00843	CcSEcCtD
Phenylpropanolamine—Agitation—Pentoxifylline—systemic scleroderma	0.00637	0.00832	CcSEcCtD
Phenylpropanolamine—Hallucination—Captopril—systemic scleroderma	0.00601	0.00784	CcSEcCtD
Phenylpropanolamine—Irritability—Lisinopril—systemic scleroderma	0.0059	0.0077	CcSEcCtD
Phenylpropanolamine—Anxiety—Pentoxifylline—systemic scleroderma	0.00588	0.00768	CcSEcCtD
Phenylpropanolamine—Ataxia—Lisinopril—systemic scleroderma	0.00581	0.00759	CcSEcCtD
Phenylpropanolamine—Confusional state—Pentoxifylline—systemic scleroderma	0.00571	0.00745	CcSEcCtD
Phenylpropanolamine—Flushing—Captopril—systemic scleroderma	0.0056	0.00732	CcSEcCtD
Phenylpropanolamine—Tachycardia—Pentoxifylline—systemic scleroderma	0.00552	0.00721	CcSEcCtD
Phenylpropanolamine—Hypotension—Pentoxifylline—systemic scleroderma	0.00529	0.00691	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Mycophenolate mofetil—systemic scleroderma	0.00529	0.00691	CcSEcCtD
Phenylpropanolamine—Tension—Captopril—systemic scleroderma	0.00516	0.00673	CcSEcCtD
Phenylpropanolamine—Urinary retention—Mycophenolate mofetil—systemic scleroderma	0.00515	0.00672	CcSEcCtD
Phenylpropanolamine—Insomnia—Pentoxifylline—systemic scleroderma	0.00512	0.00668	CcSEcCtD
Phenylpropanolamine—Nervousness—Captopril—systemic scleroderma	0.00511	0.00667	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Pentoxifylline—systemic scleroderma	0.00505	0.00659	CcSEcCtD
Phenylpropanolamine—Somnolence—Pentoxifylline—systemic scleroderma	0.00503	0.00657	CcSEcCtD
Phenylpropanolamine—Vision blurred—Captopril—systemic scleroderma	0.00495	0.00647	CcSEcCtD
Phenylpropanolamine—Constipation—Pentoxifylline—systemic scleroderma	0.00484	0.00632	CcSEcCtD
Phenylpropanolamine—Hallucination—Mycophenolic acid—systemic scleroderma	0.00472	0.00617	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Azathioprine—systemic scleroderma	0.00471	0.00615	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Pentoxifylline—systemic scleroderma	0.00466	0.00609	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Leflunomide—systemic scleroderma	0.00445	0.0058	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Mometasone—systemic scleroderma	0.00435	0.00569	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Prednisone—systemic scleroderma	0.00435	0.00567	CcSEcCtD
Phenylpropanolamine—Confusional state—Captopril—systemic scleroderma	0.00433	0.00565	CcSEcCtD
Phenylpropanolamine—Hallucination—Lisinopril—systemic scleroderma	0.00425	0.00556	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Mycophenolic acid—systemic scleroderma	0.00424	0.00554	CcSEcCtD
Phenylpropanolamine—Tachycardia—Captopril—systemic scleroderma	0.00419	0.00547	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00417	0.00545	CcSEcCtD
Phenylpropanolamine—Vision blurred—Leflunomide—systemic scleroderma	0.00408	0.00533	CcSEcCtD
Phenylpropanolamine—Tension—Mycophenolic acid—systemic scleroderma	0.00406	0.0053	CcSEcCtD
Phenylpropanolamine—Nervousness—Mycophenolic acid—systemic scleroderma	0.00401	0.00524	CcSEcCtD
Phenylpropanolamine—Hypotension—Captopril—systemic scleroderma	0.00401	0.00523	CcSEcCtD
Phenylpropanolamine—Flushing—Lisinopril—systemic scleroderma	0.00397	0.00518	CcSEcCtD
Phenylpropanolamine—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00389	0.00509	CcSEcCtD
Phenylpropanolamine—Insomnia—Captopril—systemic scleroderma	0.00388	0.00507	CcSEcCtD
Phenylpropanolamine—Tremor—Mycophenolic acid—systemic scleroderma	0.00387	0.00506	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Captopril—systemic scleroderma	0.00382	0.00499	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Lisinopril—systemic scleroderma	0.00382	0.00499	CcSEcCtD
Phenylpropanolamine—Somnolence—Captopril—systemic scleroderma	0.00381	0.00498	CcSEcCtD
Phenylpropanolamine—Agitation—Mycophenolic acid—systemic scleroderma	0.0038	0.00496	CcSEcCtD
Phenylpropanolamine—Dizziness—Pentoxifylline—systemic scleroderma	0.00374	0.00489	CcSEcCtD
Phenylpropanolamine—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.00373	0.00487	CcSEcCtD
Phenylpropanolamine—Anxiety—Leflunomide—systemic scleroderma	0.00368	0.0048	CcSEcCtD
Phenylpropanolamine—Constipation—Captopril—systemic scleroderma	0.00367	0.00479	CcSEcCtD
Phenylpropanolamine—Tension—Lisinopril—systemic scleroderma	0.00365	0.00477	CcSEcCtD
Phenylpropanolamine—Nervousness—Lisinopril—systemic scleroderma	0.00362	0.00472	CcSEcCtD
Phenylpropanolamine—Vomiting—Pentoxifylline—systemic scleroderma	0.0036	0.0047	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Prednisone—systemic scleroderma	0.00359	0.00468	CcSEcCtD
Phenylpropanolamine—Rash—Pentoxifylline—systemic scleroderma	0.00357	0.00466	CcSEcCtD
Phenylpropanolamine—Dermatitis—Pentoxifylline—systemic scleroderma	0.00357	0.00466	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Captopril—systemic scleroderma	0.00354	0.00462	CcSEcCtD
Phenylpropanolamine—Vision blurred—Lisinopril—systemic scleroderma	0.00351	0.00458	CcSEcCtD
Phenylpropanolamine—Anxiety—Mycophenolic acid—systemic scleroderma	0.00351	0.00458	CcSEcCtD
Phenylpropanolamine—Irritability—Prednisone—systemic scleroderma	0.0035	0.00457	CcSEcCtD
Phenylpropanolamine—Hypotension—Azathioprine—systemic scleroderma	0.0035	0.00457	CcSEcCtD
Phenylpropanolamine—Tremor—Lisinopril—systemic scleroderma	0.00349	0.00455	CcSEcCtD
Phenylpropanolamine—Tachycardia—Leflunomide—systemic scleroderma	0.00345	0.00451	CcSEcCtD
Phenylpropanolamine—Confusional state—Mycophenolic acid—systemic scleroderma	0.0034	0.00444	CcSEcCtD
Phenylpropanolamine—Nausea—Pentoxifylline—systemic scleroderma	0.00336	0.00439	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.00335	0.00437	CcSEcCtD
Phenylpropanolamine—Hypotension—Leflunomide—systemic scleroderma	0.0033	0.00431	CcSEcCtD
Phenylpropanolamine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00329	0.0043	CcSEcCtD
Phenylpropanolamine—Tension—Mycophenolate mofetil—systemic scleroderma	0.0032	0.00418	CcSEcCtD
Phenylpropanolamine—Insomnia—Leflunomide—systemic scleroderma	0.0032	0.00418	CcSEcCtD
Phenylpropanolamine—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00317	0.00414	CcSEcCtD
Phenylpropanolamine—Anxiety—Lisinopril—systemic scleroderma	0.00316	0.00412	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Leflunomide—systemic scleroderma	0.00315	0.00412	CcSEcCtD
Phenylpropanolamine—Hypotension—Mycophenolic acid—systemic scleroderma	0.00315	0.00412	CcSEcCtD
Phenylpropanolamine—Vomiting—Mometasone—systemic scleroderma	0.00311	0.00405	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Azathioprine—systemic scleroderma	0.00309	0.00403	CcSEcCtD
Phenylpropanolamine—Rash—Mometasone—systemic scleroderma	0.00308	0.00402	CcSEcCtD
Phenylpropanolamine—Dermatitis—Mometasone—systemic scleroderma	0.00308	0.00402	CcSEcCtD
Phenylpropanolamine—Confusional state—Lisinopril—systemic scleroderma	0.00306	0.004	CcSEcCtD
Phenylpropanolamine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00306	0.00399	CcSEcCtD
Phenylpropanolamine—Insomnia—Mycophenolic acid—systemic scleroderma	0.00305	0.00398	CcSEcCtD
Phenylpropanolamine—Constipation—Leflunomide—systemic scleroderma	0.00302	0.00395	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00301	0.00393	CcSEcCtD
Phenylpropanolamine—Somnolence—Mycophenolic acid—systemic scleroderma	0.003	0.00392	CcSEcCtD
Phenylpropanolamine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.003	0.00391	CcSEcCtD
Phenylpropanolamine—Tachycardia—Lisinopril—systemic scleroderma	0.00297	0.00387	CcSEcCtD
Phenylpropanolamine—Irritability—Methotrexate—systemic scleroderma	0.00293	0.00382	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Leflunomide—systemic scleroderma	0.00291	0.0038	CcSEcCtD
Phenylpropanolamine—Nausea—Mometasone—systemic scleroderma	0.0029	0.00379	CcSEcCtD
Phenylpropanolamine—Ataxia—Methotrexate—systemic scleroderma	0.00288	0.00377	CcSEcCtD
Phenylpropanolamine—Constipation—Mycophenolic acid—systemic scleroderma	0.00288	0.00377	CcSEcCtD
Phenylpropanolamine—Hypotension—Lisinopril—systemic scleroderma	0.00284	0.00371	CcSEcCtD
Phenylpropanolamine—Dizziness—Captopril—systemic scleroderma	0.00284	0.0037	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00278	0.00363	CcSEcCtD
Phenylpropanolamine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00277	0.00361	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Azathioprine—systemic scleroderma	0.00276	0.0036	CcSEcCtD
Phenylpropanolamine—Insomnia—Lisinopril—systemic scleroderma	0.00275	0.00359	CcSEcCtD
Phenylpropanolamine—Vomiting—Captopril—systemic scleroderma	0.00273	0.00356	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Lisinopril—systemic scleroderma	0.00271	0.00354	CcSEcCtD
Phenylpropanolamine—Rash—Captopril—systemic scleroderma	0.0027	0.00353	CcSEcCtD
Phenylpropanolamine—Dermatitis—Captopril—systemic scleroderma	0.0027	0.00353	CcSEcCtD
Phenylpropanolamine—Somnolence—Lisinopril—systemic scleroderma	0.0027	0.00353	CcSEcCtD
Phenylpropanolamine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00268	0.0035	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Leflunomide—systemic scleroderma	0.0026	0.0034	CcSEcCtD
Phenylpropanolamine—Constipation—Lisinopril—systemic scleroderma	0.0026	0.00339	CcSEcCtD
Phenylpropanolamine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.0026	0.00339	CcSEcCtD
Phenylpropanolamine—Nausea—Captopril—systemic scleroderma	0.00255	0.00333	CcSEcCtD
Phenylpropanolamine—Hallucination—Prednisone—systemic scleroderma	0.00253	0.0033	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Lisinopril—systemic scleroderma	0.0025	0.00327	CcSEcCtD
Phenylpropanolamine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00249	0.00325	CcSEcCtD
Phenylpropanolamine—Dizziness—Azathioprine—systemic scleroderma	0.00248	0.00323	CcSEcCtD
Phenylpropanolamine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00241	0.00314	CcSEcCtD
Phenylpropanolamine—Vomiting—Azathioprine—systemic scleroderma	0.00238	0.00311	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00237	0.0031	CcSEcCtD
Phenylpropanolamine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00237	0.00309	CcSEcCtD
Phenylpropanolamine—Drowsiness—Methotrexate—systemic scleroderma	0.00236	0.00309	CcSEcCtD
Phenylpropanolamine—Rash—Azathioprine—systemic scleroderma	0.00236	0.00308	CcSEcCtD
Phenylpropanolamine—Dermatitis—Azathioprine—systemic scleroderma	0.00236	0.00308	CcSEcCtD
Phenylpropanolamine—Flushing—Prednisone—systemic scleroderma	0.00236	0.00308	CcSEcCtD
Phenylpropanolamine—Dizziness—Leflunomide—systemic scleroderma	0.00234	0.00305	CcSEcCtD
Phenylpropanolamine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00228	0.00297	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Prednisone—systemic scleroderma	0.00227	0.00296	CcSEcCtD
Phenylpropanolamine—Vomiting—Leflunomide—systemic scleroderma	0.00225	0.00294	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Lisinopril—systemic scleroderma	0.00224	0.00292	CcSEcCtD
Phenylpropanolamine—Dizziness—Mycophenolic acid—systemic scleroderma	0.00223	0.00291	CcSEcCtD
Phenylpropanolamine—Rash—Leflunomide—systemic scleroderma	0.00223	0.00291	CcSEcCtD
Phenylpropanolamine—Dermatitis—Leflunomide—systemic scleroderma	0.00223	0.00291	CcSEcCtD
Phenylpropanolamine—Nausea—Azathioprine—systemic scleroderma	0.00222	0.0029	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00219	0.00286	CcSEcCtD
Phenylpropanolamine—Vomiting—Mycophenolic acid—systemic scleroderma	0.00214	0.0028	CcSEcCtD
Phenylpropanolamine—Rash—Mycophenolic acid—systemic scleroderma	0.00213	0.00278	CcSEcCtD
Phenylpropanolamine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00212	0.00277	CcSEcCtD
Phenylpropanolamine—Nausea—Leflunomide—systemic scleroderma	0.0021	0.00274	CcSEcCtD
Phenylpropanolamine—Vision blurred—Prednisone—systemic scleroderma	0.00208	0.00272	CcSEcCtD
Phenylpropanolamine—Agitation—Prednisone—systemic scleroderma	0.00203	0.00265	CcSEcCtD
Phenylpropanolamine—Dizziness—Lisinopril—systemic scleroderma	0.00201	0.00262	CcSEcCtD
Phenylpropanolamine—Nausea—Mycophenolic acid—systemic scleroderma	0.002	0.00262	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00196	0.00256	CcSEcCtD
Phenylpropanolamine—Vomiting—Lisinopril—systemic scleroderma	0.00193	0.00252	CcSEcCtD
Phenylpropanolamine—Rash—Lisinopril—systemic scleroderma	0.00192	0.0025	CcSEcCtD
Phenylpropanolamine—Dermatitis—Lisinopril—systemic scleroderma	0.00191	0.0025	CcSEcCtD
Phenylpropanolamine—Anxiety—Prednisone—systemic scleroderma	0.00188	0.00245	CcSEcCtD
Phenylpropanolamine—Nausea—Lisinopril—systemic scleroderma	0.0018	0.00236	CcSEcCtD
Phenylpropanolamine—Tachycardia—Prednisone—systemic scleroderma	0.00176	0.0023	CcSEcCtD
Phenylpropanolamine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00176	0.0023	CcSEcCtD
Phenylpropanolamine—Vision blurred—Methotrexate—systemic scleroderma	0.00174	0.00227	CcSEcCtD
Phenylpropanolamine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00169	0.00221	CcSEcCtD
Phenylpropanolamine—Rash—Mycophenolate mofetil—systemic scleroderma	0.00168	0.00219	CcSEcCtD
Phenylpropanolamine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00168	0.00219	CcSEcCtD
Phenylpropanolamine—Insomnia—Prednisone—systemic scleroderma	0.00163	0.00213	CcSEcCtD
Phenylpropanolamine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00158	0.00206	CcSEcCtD
Phenylpropanolamine—Constipation—Prednisone—systemic scleroderma	0.00154	0.00201	CcSEcCtD
Phenylpropanolamine—Confusional state—Methotrexate—systemic scleroderma	0.00152	0.00199	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Prednisone—systemic scleroderma	0.00149	0.00194	CcSEcCtD
Phenylpropanolamine—Hypotension—Methotrexate—systemic scleroderma	0.00141	0.00184	CcSEcCtD
Phenylpropanolamine—Insomnia—Methotrexate—systemic scleroderma	0.00136	0.00178	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Methotrexate—systemic scleroderma	0.00134	0.00176	CcSEcCtD
Phenylpropanolamine—Somnolence—Methotrexate—systemic scleroderma	0.00134	0.00175	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Prednisone—systemic scleroderma	0.00133	0.00174	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Methotrexate—systemic scleroderma	0.00124	0.00162	CcSEcCtD
Phenylpropanolamine—Dizziness—Prednisone—systemic scleroderma	0.00119	0.00156	CcSEcCtD
Phenylpropanolamine—Vomiting—Prednisone—systemic scleroderma	0.00115	0.0015	CcSEcCtD
Phenylpropanolamine—Rash—Prednisone—systemic scleroderma	0.00114	0.00149	CcSEcCtD
Phenylpropanolamine—Dermatitis—Prednisone—systemic scleroderma	0.00114	0.00148	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Methotrexate—systemic scleroderma	0.00111	0.00145	CcSEcCtD
Phenylpropanolamine—Nausea—Prednisone—systemic scleroderma	0.00107	0.0014	CcSEcCtD
Phenylpropanolamine—Dizziness—Methotrexate—systemic scleroderma	0.000997	0.0013	CcSEcCtD
Phenylpropanolamine—Vomiting—Methotrexate—systemic scleroderma	0.000959	0.00125	CcSEcCtD
Phenylpropanolamine—Rash—Methotrexate—systemic scleroderma	0.000951	0.00124	CcSEcCtD
Phenylpropanolamine—Dermatitis—Methotrexate—systemic scleroderma	0.00095	0.00124	CcSEcCtD
Phenylpropanolamine—Nausea—Methotrexate—systemic scleroderma	0.000896	0.00117	CcSEcCtD
